GA-ASI Tests PT6 E-Series Engine From Pratt & Whitney on MQ-9B RPA

Featured Image for General Atomics Aeronautical Systems, Inc.

SAN DIEGO, Aug. 16, 2022 (GLOBE NEWSWIRE) — On July 29, 2022, General Atomics Aeronautical Systems, Inc. (GA-ASI) tested a PT6 E-Series model turboprop engine from Pratt & Whitney Canada on GA-ASI’s MQ-9B Remotely Piloted Aircraft (RPA). Multiple full-power engine tests were performed at GA-ASI’s Desert Horizon flight operations facility in El Mirage, California.

“We’ve enjoyed a long-term relationship with Pratt & Whitney,” said GA-ASI President David R. Alexander. “Integrating their PT6 E-Series engine onto our MQ-9B SkyGuardian® aircraft offers an alternate option for future customers that includes a 33 percent increase in power, dual channel electronic propeller and engine control system, as well as all the benefits of the PT6 engine family.”

The PT6 E-Series is a reliable and versatile turboprop engine family that will deliver the performance characteristics required as GA-ASI continues its development of MQ-9B capabilities.

“Our PT6 E-series is the ideal engine for this mission and we look forward to working with General Atomics on this important program,” said Jill Albertelli, president of Pratt & Whitney Military Engines.

MQ-9B represents the next generation of RPA system having demonstrated airborne endurance of more than 40 hours in certain configurations, automatic takeoffs and landings under SATCOM-only control, as well as a GA-ASI developed Detect and Avoid system. Its development is the result of a company-funded effort to deliver an RPA that can meet the stringent airworthiness certification requirements of various military and civil authorities.

GA-ASI has enjoyed a long-term collaboration with Pratt & Whitney for over a decade with their turbofan engine for GA-ASI’s MQ-20 Avenger RPA.

About GA-ASI

General Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable remotely piloted aircraft (RPA) systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With more than seven million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent flight that enables situational awareness and rapid strike. The company also produces a variety of ground control stations and sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas. For more information, visit www.ga-asi.com.

Avenger, Lynx, Predator, SeaGuardian and SkyGuardian are registered trademarks of General Atomics Aeronautical Systems, Inc. 

CONTACT:
GA-ASI Media Relations
General Atomics Aeronautical Systems, Inc.
+1 (858) 524-8101
ASI-MediaRelations@ga-asi.com

Related Images

Image 1

This content was issued through the press release distribution service at Newswire.com.

Attachment

RoosterBio and AGC Biologics Announce Collaboration to Accelerate Manufacturing of Cell and Exosome Therapies

New partnership delivers clinically proven products and manufacturing processes for advanced therapies

SEATTLE, Aug. 16, 2022 (GLOBE NEWSWIRE) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced today a strategic partnership with RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and bioprocess development services.

The partnership creates an end-to-end solution for the development and production of hMSC and exosome therapeutics leveraging RoosterBio’s well-established cell and media products and process development services, coupled with AGC Biologics’ global cell and gene therapy manufacturing capabilities.

RoosterBio will utilize its extensive portfolio of cell and media products to develop robust, scalable processes for hMSC and exosome therapies.  These capabilities include genetic engineering of cells and exosomes to express therapeutic targets, upstream processing in both 2D flask and 3D bioreactor systems, downstream purification to achieve desired purity and potency, and comprehensive analytical characterization of the resulting formulated cell or exosome therapy.

AGC Biologics will utilize its global network to provide full Process Development, cGMP Manufacturing, Quality Control and Regulatory services for pre-clinical and phase I/II clinical trials, with the ability to scale to Phase III and commercial production. The CDMO also offers a range of development and manufacturing scales that can be tailored to the specific needs of drug developers in different regions worldwide. The AGC Biologics scientific teams have over two decades of experience in advanced therapy production and manufacturing, and have brought three commercial products to market. The global CDMO’s network of sites offers the latest cell therapy technologies and processes, including allogenic and autologous systems and techniques.

“AGC Biologics is happy to be partnering with RoosterBio. They have a reliable method for producing engineered cells and exosomes that can help developers create life-saving therapies,” said Patricio Massera, Chief Executive Officer of AGC Biologics. “When you combine their work and expertise with AGC Biologics’ scientific knowledge and global manufacturing services, it creates a comprehensive offering that can help these developers save time and money, and get their treatments in the hands of patients in need.”

“AGC Biologics has an outstanding track record of success in the manufacture of clinical and commercial advanced therapies and an ever-expanding global network to meet the needs of our customers,” said Tim Kelly, Chief Executive Officer of RoosterBio. “Biopharmaceutical companies striving to develop engineered cell and exosome therapies require proven, flexible technologies paired with reliable and scalable manufacturing solutions.  This collaboration was conceived to deliver that end-to-end solution for our customers and I am thrilled to partner with AGC Biologics to translate our hMSC and exosome technologies into advanced therapy products that have the potential to bring curative treatments to patients in need.”

More details on this partnership and the joint offering from RoosterBio and AGC Biologics will be released in the coming months.

AGC Biologics’ global cell therapy services and viral vector capabilities utilize proprietary platforms developed to address the evolving advanced therapies market. To learn more about the company and its complete list of CDMO services visit www.agcbio.com.

About RoosterBio
RoosterBio accelerates human mesenchymal stem/stromal cell (hMSC) and extracellular vesicle (EV) product and process development to fuel the rapid commercialization of scalable regenerative cures. Our high-quality hMSCs, bioprocess media, genetic engineering tools, and EV production solutions are paired with expert bioprocessing knowledge to progress therapeutic developers from concept to first-in-human testing and commercial manufacturing at reduced cost and increased productivity. With optimized, scalable processes, Type 2 Drug Master Files, and cGMP products, we have enabled therapeutic programs to traverse their path to clinical translation in under 1 year. RoosterBio is driven by client’s success and creating a world where safe and effective regenerative medicines are rapidly developed and widely available on a global scale.

http://www.roosterbio.com

LinkedIn: RoosterBio

About AGC Biologics
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 2,500 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. To learn more, visit www.agcbio.com.

LinkedIn: AGC Biologics

Attachment

Nick McDonald
AGC Biologics
nmcdonald@agc.com

With 3Brain AG’s Accura-3D microchip, a first-in-class cell-electronic interface enters the market

In collaboration with Swiss precision manufacturer CSEM, 3Brain AG has announced an exciting 3D microchip for their brain-on-chip portfolio. This first-in-class cell-electronic interface technology will allow scientists to study the complexity of 3D cellular networks at unrivalled scale and precision – and to gain novel mechanistic insights into the inner workings of the most complex structure in the universe: the human brain.

3D CMOS chip for connecting electroactive tissues and organoids to software

WÄDENSWIL, Switzerland, Aug. 16, 2022 (GLOBE NEWSWIRE) — Understanding how organs form and how their cells behave is essential to finding the causes and treatment for developmental disorders, as well as understanding certain diseases. However, studying most organs in live animals or humans is technically difficult, expensive, and invasive.

3D CMOS chip for connecting electroactive tissues and organoids to software

  • 3Brain AG and Swiss applied research institute CSEM unveil a first-in-class 3D CMOS microchip to probe intelligent networks within the complex cytoarchitecture of electroactive 3D tissues and brain organoids.
  • Accura-3D will allow researchers to explore new biological questions at unprecedented depths and resolution and discover pharmacologically relevant biomarkers. 3Brain AG’s bidirectional pixel array technology at the heart of Accura-3D is expanding non-destructive functional imaging beyond optic and optogenetic approaches.
  • Equipped with sensory gold-electrodes mounted on thousands of biopolymer-covered microneedles and dozens of integrated microfluidic channels, Accura-3D exhibits an innovative brain-on-chip design to support high-throughput phenotypic assays, neurotoxicity screenings, and drug discovery approaches.
  • Accura-3D chips are fully compatible with existing hardware devices to give users exciting results from day 1.

New biotechnologies like human-derived stem cells offer to recapitulate the complexity and functionality of human tissues and allow for the generation of novel and exciting test systems, including multicellular models, three-dimensional cultures and organ-on-a-chip. But the increasing complexity of these model systems brings new challenges for researchers and companies. Novel methods and devices are needed to meet accuracy, precision, sensitivity, specificity, and repeatability requirements for the evaluation of physiologically relevant endpoints in these systems.

Electroactive tissues like the heart, brain or nervous system are built up from networks of cells that communicate with each other via rapid depolarization of their membrane potential mediated by the opening and closing of voltage-gated ion channels. Cell-electronic interfaces are devices that record or instigate dynamic changes in extracellular field potential close to the plasma membrane, corresponding to the flux of ions into or out of cells, and connect these biosignals to computers in real-time. 3Brain’s technology can connect to thousands of cells at the same time and process biosignals at 20.000 frames per second in a spatially resolved pixel array, not unlike an ultra-high-speed HD camera, thereby effectively expanding the concept of label-free functional imaging beyond optical approaches.

Currently, cell-electronic interfaces like patch clamp and, more recently, high-density multi-electrode arrays are limited to 2D and suffer many limitations when it comes to measuring 3D model systems like brain organoids or tissue preparation because they cannot reach the necessary proximity to physiologically relevant cells.

To tackle these challenges, 3Brain AG paired up with CSEM, a primary Swiss applied research institute specialized in precision manufacturing, to develop a 3D cell-electronic interface based on complementary metal-oxide semiconductor (CMOS) technology. This first-in-class 3D CMOS microchip (named Accura-3D) is equipped with sensory gold-electrodes mounted on thousands of biopolymer-covered microneedles. Accura-3D enables the investigation of 3D cellular networks at unprecedented depths and resolution, which will open up unrivalled access to the complexities of biological systems. With only half the diameter of human hair, biopolymer-covered microneedles bypass damaged and surface cell layers of 3D model systems without disrupting the overall cytoarchitecture, thus retaining full biological integrity. Furthermore, custom-made microfluidic channels at the basis of Accura-3D were designed to mitigate physiological impact of varied diffusion gradients for oxygen, nutrients and compounds, a common issue when 3D models are measured with in vitro devices built for 2D.

With the addition of Accura-3D to their brain-on-chip portfolio, 3Brain AG has announced that the 3D chip design will be fully compatible and integrated with their existing technology platforms.

Accura-3D bypasses damaged cell layers from tissue slices to improve signal depths and reproducibility

What we really want is to empower researchers to ask new and daring biological questions that have so far been impossible to investigate,” says Mauro Gandolfo, CEO and co-founder of 3Brain AG. “Our cell-electronic interfaces expand the concept of optics-free functional imaging, all without the need for biological markers, fluorescent proteins or genetic manipulation of cellular networks. With Accura-3D, we created a first-in-class solution that can directly access the complex cytoarchitecture of 3D tissues and brain organoids. The biggest challenges are taking the vast amounts of data coming from cells and processing them without losing critical information in real-time. Accura-3D does a lot of the heavy lifting with on-chip processing, signal amplification and noise filtering, which basically makes the chip itself intelligent. This integrated intelligence is a remarkable distinction from other instruments in the preclinical space and helps researchers to record or even actively stimulate biosignals at unprecedented depths. There is just no comparable solution out there.”

3Brain AG has been working on advanced microchip technology applied to life science for more than 15 years. Alessandro Maccione, CSO and co-founder of 3Brain AG, says, “We are very attentive to the opportunities offered by advanced cell models such as spheroids and organoids. We already have results showing that Accura-3D is vastly superior in measuring physiologically relevant cells and biosignals. We started focusing on brain organoids because of their relevance to model devastating developmental and neurodegenerative diseases of the brain that pose a high burden for our society, for example, Alzheimer’s and epilepsy. Scientifically, Accura-3D is super exciting, because it will allow us to peek deeper into the inner workings of tissues and organoids and ask questions previously out of reach. Why, where and how does spontaneous activity emerge in brain organoids and how do coordinated brain waves start? Does neuronal activity shape cytoarchitecture or is it the other way round? How does connectivity evolve over time? Are there differences in neuronal development in organoids derived from healthy versus at-risk patients? The possibilities are almost endless, Accura-3D is opening the door into the galaxy of our own minds, and this is what I think many scientists will want to explore with us. For many, a three-dimensional cell-electronic interface which can collect cellular information directly from the inside of tissues and organoids might sound like science fiction. We made it a science fact.”

Accura-3D has integrated microfluidic channels to guarantee efficient oxygen, nutrient, and compound diffusion

For the development of Accura-3D, 3Brain has partnered with Swiss precision manufacturing research institute CSEM to push the boundaries of what is possible with 3D microfabrication. Michele Palmieri, VP Micro and Nanosystems at CSEM, was ecstatic about what they achieved. “Together with 3Brain AG, our team has been developing cutting-edge microfabrication processes to create a dense, vertically developed microneedle array on top of pre-processed advanced CMOS wafer. Such tall, vertically bound array goes above and beyond the state-of-the-art for microelectrode arrays, with an extreme electrode vertical/horizontal aspect ratio in excess of 8. To build it, it takes more than 80 process units, including photolithography and etch, multi-metal stack deposition, noble metal electroplating, structural polymeric material, planarization, etc. … to put it simply, it’s a microtechnology masterpiece – a technologist’s and neurobiologist’s ultimate dream.”

About 3Brain AG

3Brain is the world’s first company to connect cells with sophisticated biosignal processing microchips in vitro. The company has intensively worked on CMOS-powered cell-electronic interfaces with the aim of boosting research activity in biomedical and neurosciences, ophthalmology and cardiology. After being the first to develop and introduce CMOS-based HD-MEA (high-density microelectrode array), 3Brain has now created another first-in-class technology with Accura-3D.

About CSEM – Centre suisse d’électronique et de microtechnique SA

CSEM is a Swiss private, non-profit research and technology organization with +35 years of Deep Tech development and transfer to industry. CSEM major research axes are Precision Manufacturing, Digital Technologies and Sustainable Energy.

Contact information:
Mauro Gandolfo
CEO
mauro.gandolfo@3brain.com
For media inquiries:
Philipp Markolin
Scientific Marketing Specialist
philipp.markolin@3brain.com

Related Images

Image 1: 3D CMOS chip for connecting electroactive tissues and organoids to software

Image 2: Accura-3D bypasses damaged cell layers from tissue slices to improve signal depths and reproducibili

Image 3: Accura-3D has integrated microfluidic channels to guarantee efficient oxygen, nutrient, and compound

This content was issued through the press release distribution service at Newswire.com.

Attachment

WHR Global Announces New President, Chris Lagerman

WHR also Promotes Tenured Employees to Director of Global Operations and Client Services Manager

MILWAUKEE, Aug. 16, 2022 (GLOBE NEWSWIRE) — WHR Global, Inc. (WHR), a leader in the global employee relocation industry, announced that Chris Lagerman will be its new President, effective immediately. This promotion reflects Chris’ dedication to WHR and the global mobility industry. Over his 20-year tenure at WHR, Chris previously served as a Relocation Counselor, Client Services Manager and most recently, as Director of Global Operations (DO).

As DO, Chris guided a team of Client Services Managers throughout WHR’s offices in the US, Switzerland and Singapore. WHR helps some of the largest global organizations and has relocated tens of thousands of employees to over 100 countries worldwide. WHR specializes in providing each expatriate with a dedicated relocation team, white-glove service and 24/7 availability for their entire relocation journey. As a testament to Chris’ DO success, WHR only lost one corporate client in its 27-year history, which is a direct result of Chris’ passion for best-in-class service.

WHR CEO Roger Thrun believes Chris will continue to drive the success of WHR’s services and technology. “Chris has been instrumental to our growth in the last 20 years and will continue the velocity of our global expansion. I am very proud that he is part of WHR,” said Thrun.

“I’m honored and grateful for this opportunity and I look forward to driving WHR’s further growth,” said Lagerman.

Effective immediately, WHR also announced that Heather Hess has been promoted to Director of Global Operations, leading all Client Services Managers in the US, Switzerland and Singapore. WHR also announced that Peter Janotta has been promoted to Client Services Manager, effective immediately. Heather and Peter have been at WHR for 14 years each, embodying WHR’s service-oriented approach to global mobility and successfully managing relocation programs for Fortune 500 companies.

About WHR Global
WHR Global (WHR) is a private, client-driven global relocation management company distinguished by its best-in-class service delivery and cutting-edge, proprietary technology. WHR has offices in the US, Switzerland and Singapore. With its 100% client retention rate for the past decade, WHR continues to position itself as the trusted leader in global employee relocation. WHR lives by its vision of Advancing Lives Forward®.

To learn more about WHR, visit https://www.whrg.com, or follow on LinkedInTwitter and Facebook.

Media Contact: Mindy Stroiman, Corporate Writer
Mindy.Stroiman@whrg.com
+1-262-523-7510

LaunchDarkly Increases International Presence in EMEA

Enterprise Software Leader Laurie Maclachlan to Head Up Region

OAKLAND, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) — LaunchDarkly, the leader in feature management today announced it hired Laurie Maclachlan as its Vice President and General Manager of EMEA (Europe, Middle East and Africa). Maclachlan brings more than 20 years of enterprise software sales and leadership experience, specifically in helping pre-IPO technology companies from Silicon Valley grow their European businesses. Maclachlan will work with an already thriving team to strengthen the company’s presence in the region.

“EMEA companies are rethinking how they deploy software and that has brought upon a strong demand for feature management technology,” said Jeremy Smith, Chief Revenue Officer at LaunchDarkly. “Laurie will be focused on two critical missions as our business expands in EMEA – helping LaunchDarkly meet our customers’ needs and hiring a first-class, cross functional team in areas such as sales, marketing, engineering and human resources.”

Prior to joining LaunchDarkly, Maclachlan was the AVP for the Northern EMEA region at HashiCorp, and he has held similar leadership roles at technology companies such as Hortonworks and Apigee. Additionally, his blend of technology and business experience includes working at companies such as Salesforce and Accenture. Laurie graduated with a B.A. in International Business & Modern Languages from the University of Strathclyde and is fluent in several languages including English, French and German.

Maclachlan joins LaunchDarkly as the company continues its path towards success both in the US and in international markets. In addition to working with EMEA-based companies like Checkout.com, ITV and Marks & Spencer, LaunchDarkly has also won prestigious technology and business industry awards, including receiving the 2022 CODiE Award for Best DevOps Tool and recently being named number 34 on the influential Forbes Cloud 100 list.

“LaunchDarkly is at the forefront of an incredibly exciting software sector and the company is truly ushering in a new way for organizations of all sizes to develop and deploy digital products,” said Laurie Maclachlan, VP & GM EMEA at LaunchDarkly. “The European market is ripe with an abundance of potential and demand for LaunchDarkly’s technology, and the focus will be to meet these customers’ needs while also continuing to build out the team and its presence in the region.”

About LaunchDarkly
LaunchDarkly isn’t just a leader in feature management — it’s the first scalable feature management platform. Feature management allows development teams to innovate faster by fundamentally transforming how software is delivered to customers. With the ability to gradually release new software features to any segment of users on any platform, DevOps teams can standardize safe releases at scale, accelerate their journey to the cloud, and collaborate more effectively with business teams. Today, LaunchDarkly deploys peaks of 20 trillion feature flags a day, and that number continues to grow. Founded in 2014 in Oakland, California by Edith Harbaugh and John Kodumal, LaunchDarkly has been named on the Forbes Cloud 100 list, InfoWorld’s 2021 Technology of the Year list, and the Enterprise Tech 30 list. Learn more at launchdarkly.com.

Contact

launchdarkly (at) launchsquad.com